Prospective randomized controlled trial between lemborexant and benzodiazepine for pancreatobiliary patients with high risk factor of delirium

Prospective randomized controlled trial between lemborexant and benzodiazepine for pancreatobiliary patients with high risk factor of delirium - Prospective randomized controlled trial between lemborexant and benzodiazepine for pancreatobiliary patients with high risk factor of delirium

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000054351

Enrollment

Registered

2024-06-01

Start date

2024-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatobiliary patents with high risk factor of delirium

Interventions

benzodiazepine lemborexant

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Inpatients with pancreatobiliary disease 2 Patients who are complicated with risk factor associated with delirium 3 Complicating with insomnia 4 Age 18-99

Exclusion criteria

Exclusion criteria: 1 Undertaken antipsychotic drugs 2 Undertaken sleeping pills 3 Refusal to participate this study

Design outcomes

Primary

Measure	Time frame
The incidence rate of delirium	—

Countries

Japan

Contacts

Public ContactTakeshi Ogura

Osaka Medical and Pharmaceutical University Hospital Endoscopy Center

oguratakeshi0411@yahoo.co.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026